Luke Evnin Sells 87,425 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $0.45, for a total transaction of $39,341.25. Following the completion of the transaction, the director directly owned 831,635 shares of the company’s stock, valued at $374,235.75. This trade represents a 9.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total transaction of $31,936.50.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total transaction of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total transaction of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $28,336.50.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total transaction of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.49 on Thursday. The stock has a market capitalization of $23.81 million, a PE ratio of -0.40 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 52-week low of $0.40 and a 52-week high of $2.38. The company has a 50-day simple moving average of $0.76 and a two-hundred day simple moving average of $0.76.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HOWL. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the first quarter worth about $79,000. Marshall Wace LLP purchased a new position in Werewolf Therapeutics in the second quarter worth about $113,000. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the second quarter valued at approximately $48,000. Jane Street Group LLC purchased a new stake in Werewolf Therapeutics during the second quarter valued at approximately $409,000. Finally, Bank of America Corp DE increased its holdings in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.